|
CA2880105A1
|
|
Detection of the er.alpha./src/pi3k complex as predictive marker in breast cancer
|
|
WO2013174859A1
|
|
Screening methods for identifying compounds which interfere with coup-tfii (nr2f2) or coup-tfi (nr2f1)
|
|
CA2858466A1
|
|
Treatment of cancer by inhibition of the myd88/erk map kinase interaction
|
|
WO2013007801A1
|
|
Predictive tool for response to anti-igf-1r antibody therapy in cancer patients
|
|
WO2013007640A1
|
|
Pla2r1 as anti-tumoral compound and as biomarker for the detection of cancer
|
|
EP2528619A1
|
|
Screening method for identifying compounds which block tumour growth by inducing irreversible senescence in tumour cells
|
|
WO2011051495A1
|
|
Determination of 17q gain in neuroblastoma patients by analysis of circulating dna
|
|
CA2751977A1
|
|
C-cbl and antagonists thereof for the treatment and diagnosis of cancer
|
|
CA2749049A1
|
|
Method for the selection of endothelial cells death inducers via netrin-1 and its applications
|
|
WO2010076334A2
|
|
Intraoperative diagnosis of primary tumors and secondary tumors or metastases
|
|
EP2275569A1
|
|
ZNF217 a new prognostic and predictive biomarker of recurrent, invasive and metastatic phenotypes in cancer
|
|
CA2724830A1
|
|
Inhibition of the nt-3:trkc bound and its application to the treatment of cancer such as neuroblastoma
|
